Lagerstandorte

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Vorbehaltlich Verfügbarkeit

Dokumentation

MSDS herunterladen

Beispiel-COA herunterladen

Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.

1346603-25-5Moxifloxacin Related Compound G

● Auf Lager

Katalog-Nr.::	VL106010
CAS-Nr.::	1346603-25-5
Summenformel::	C21H25ClFN3O4
Molare Masse::	437.89

Angebot anfordern

Zur RFQ-Liste hinzufügen

Zusätzliche Informationen zu CAS 1346603-25-5

Parent drug

Moxifloxacin

IUPAC-Name

1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aR, 7aR)-octahydro-6H-pyrrolo[3, 4-b]pyridin-6-yl]-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid hydrochloride

Synonyme

Moxifloxacin HCl (R, R)-Isomer ; (4aR, 7aR)-Moxifloxacin Hydrochloride ;ent-Moxifloxacin Hydrochloride;d-Moxifloxacin Hydrochloride; 1-Cyclopropyl-6-fluoro-1, 4-dihydro-8-methoxy-7-[(4aR, 7aR)-octahydro-6H-pyrrolo[3, 4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic Acid Hydrochloride; d-Moxifloxacin Hydrochloride; (4R, 7R)-Moxifloxacin Hydrochloride;

Beschreibung

Moxifloxacin Related Compound G (CAS No: 1346603-25-5) or Moxifloxacin HCl (R, R)-Isomer is an impurity present in moxifloxacin that shows antibacterial activity including all major upper and lower respiratory tract pathogens, is one of the most active fluoroquinolones against pneumococci.

References

Kumar, Y. Ravindra., et al. â€œStructural Identification and Characterization of Impurities in Moxifloxacin.â€ Journal of Pharmaceutical and Biomedical Analysis, vol. 34, no. 5, Mar. 2004, pp. 1125â€“29, https://doi.org/10.1016/j.jpba.2003.11.012. Barman Balfour, Julia A., and Harriet M. Lamb. â€œMoxifloxacin.â€ Drugs, vol. 59, no. 1, Jan. 2000, pp. 115â€“39, https://doi.org/10.2165/00003495-200059010-00010.